secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0000950170-24-051566
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera Therapeutics Q1 2024 net loss $48.6M; cash $745M; pipeline progresses
----------------------------------------------------------------------------

- Net loss $48.6M in Q1 2024 vs $40.9M in Q1 2023; collaboration revenue $10.3M.
- Cash, cash equivalents and investments $745M as of March 31, 2024.
- Cash runway extended into first half of 2027 following $301M equity offering.
- KT-474 IRAK4 degrader Phase 2 trials in HS and AD ongoing; topline data H1 2025.
- KT-621 STAT6 degrader Phase 1 start H2 2024; KT-294 TYK2 degrader Phase 1 start H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000095017024051566/0000950170-24-051566-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000095017024051566/kymr-20240502.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-051566

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer